Subtype
Renal Non-Clear Cell Carcinoma
CI-CAN-00009407Explore in graph →
37 active trials5 evidence items
- OncoTree
- NCCRCC
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00009407Explore in graph →
Clinical trials
71 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (4)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT02654340 | Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)(TuScCom) | terminated | — | 20 | CENTOGENE GmbH RostockINDUSTRY | 8 | Feb 10, 2023 | clinicaltrials |
| NCT02837991 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma | terminated | Phase 1 | 16 | Celldex TherapeuticsINDUSTRY | 1 | Jun 4, 2020 | clinicaltrials |
| NCT00098618 | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | terminated | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Oct 16, 2025source: clinicaltrials